National Institutes of Health researchers have isolated a set of promising, tiny antibodies, or "nanobodies" against SARS-CoV-2 virus that were produced by a llama named Cormac.
Preliminary results published in Scientific Reports suggest that at least one of these nanobodies, called NIH-CoVnb-112, could prevent infections and detect virus particles by grabbing hold of SARS-CoV-2 spike proteins.
In addition, the nanobody appeared to work equally well in either liquid or aerosol form, suggesting it could remain effective after inhalation.
SARS-CoV-2 is the virus that causes COVID-19.
The study was led by a pair of neuroscientists, Thomas J.
"T.J." Esparza, B.S., and David L.
Brody, M.D., Ph.D., who work in a brain imaging lab at the NIH's National Institute of Neurological Disorders and Stroke (NINDS).
A nanobody is a special type of antibody naturally produced by the immune systems of camelids, a group of animals that includes camels, llamas, and alpacas.
On average, these proteins are about a tenth the weight of most human antibodies.
Because nanobodies are more stable, less expensive to produce, and easier to engineer than typical antibodies, a growing body of researchers, including Esparza and Dr. Brody, have been using them for medical research.
